Monographie - Ondansetron hydrochloride

Pēdējā atjaunošana :
28/04/2024

Ondansetron hydrochloride

Ķīmiskā uzbūve

Oriģinālais nosaukums

Tirdzniecības nosaukumi ir apzīmējoši un palīgvielas var atšķirties dažādām valstīm un laboratorijām

Amal	Meksika
Ansentron	Brazīlija
Antivon	Čīle, Meksika
Atossa	Polija
Avessaron	Beļģija
Axisetron	Vācija
Bryterol	Ekvadora, Kolumbija
Cellondan	Vācija
Chemoset	Maroka
Danac	Meksika
Danofran	Ēģipte
Danset	Ēģipte
Dantron	Dienvidāfrikas Republika, Maroka
Dasentron	Argentīna, Saūda Arābija
Dismolan	Argentīna, Venecuēla
Donset	Indija
Emeset	Indija, Rumānija, Turcija
Emetron	Polija, Ungārija
Emistop	Meksika, Peru
Indansen	Meksika
Nausetron	Dienvidāfrikas Republika
Ondansan	Austrija
Ondatron	Vācija
Setronon	Horvātija
Vomiz	Dienvidāfrikas Republika
Yatrox	Spānija
Zofer	Turcija
Zofran	Amerikas Savienotās Valstis, Apvienotie Arābu Emirāti, Argentīna, Austrija, Beļģija, Dānija, Ēģipte, Ekvadora, Holande, Īrija, Islande, Itālija, Jaunzēlande, Kanāda, Kolumbija, Lielbritānija, Luksemburga, Malaizija, Maroka, Norvēģija, Peru, Polija, Portugāle, Saūda Arābija, Somija, Šveice, Turcija, Ungārija, Vācija, Zviedrija
Zofron	Grieķija
Zontron	Turcija
Zophren	Francija, Tunisija
Zotrix	Zviedrija

Literatūras saraksts : Ondansetron hydrochloride

	Tips	Publicēšana
3	Žurnāls	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
6	Žurnāls	Trissel LA, Xu QA, Martinez JF, Fox JL. Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22 and 32°C. Am J Hosp Pharm 1994 ; 51: 2138-2142.
16	Žurnāls	Chung KC, Moon YSK, Chin A, Ulrich WU, Gill MA. Compatibility of ondansetron hydrochloride and piperacillin sodium-tazobactam sodium during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1554-1556.
18	Žurnāls	Pompilio FM, Fox JL, Inagaki K, Burm JP, Jhee S, Gill MA. Stability of ranitidine hydrochloride with ondansetron hydrochloride or fluconazole during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 391-394.
23	Žurnāls	Evrard B, Ceccato A, Gaspard O, Delattre L, Delporte JP. Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride and in 5% dextrose injection. Am J Health-Syst Pharm 1997 ; 54: 1065-1068.
25	Žurnāls	McGuire TR, Narducci WA, Fox JL. Compatibility and stability of ondansetron hydrochloride, dexamethasone, and lorazepam in injectable solutions. Am J Hosp Pharm 1993 ; 50: 1410-1414.
26	Žurnāls	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL. Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags. Am J Health-Syst Pharm 1997 ; 54: 915-920.
30	Žurnāls	Hagan RL, Mallett MS, Fox JL. Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in infusion bags and syringes for 32 days. Am J Health-Syst Pharm 1996 ; 53: 1431-1435.
36	Žurnāls	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
47	Žurnāls	Burm JP, Jhee SS, Chin A, Moon YSK. Stability of paclitaxel with ondansetron or ranitidine hydrochloride during simulated Y site administration. Am J Hosp Pharm 1994 ; 51: 1201-1204.
50	Žurnāls	Fleming RA, Olsen DJ, Savage PD, Fox JL. Stability of ondansetron hydrochloride and cyclophosphamide in injectable solutions. Am J Health-Syst Pharm 1995 ; 52: 514-516.
52	Žurnāls	Kirkham JC, Rutherford ET, Cumingham GN, Daneshmand KA, Falls AL. Stability of ondansetron hydrochloride in a total parenteral nutrient admixture. Am J Health-Syst Pharm 1995 ; 52: 1557-1558.
53	Žurnāls	Henry DW, Marshall JL, Nazzar OD, Fox JL, Leff RD. Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion. Am J Health-Syst Pharm 1995 ; 52: 2570-2573.
59	Žurnāls	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
81	Žurnāls	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Žurnāls	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Žurnāls	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
93	Žurnāls	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Žurnāls	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
113	Žurnāls	Jhee SS, Jeong EW, Chin A, Inagaki K, Fox JL, Gill MA. Stability of ondansetron hydrochloride stored in a disposable, elastomeric infusion device at 4°C. Am J Hosp Pharm 1993 ; 50: 1918-1920.
132	Žurnāls	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
150	Žurnāls	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
169	Žurnāls	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
179	Žurnāls	Stiles ML, Allen LV Jr, Fox JL. Stability of ondansetron hydrochloride in portable infusion-pump reservoirs. Am J Hosp Pharm 1992 ; 49: 1471-1473.
183	Žurnāls	Bosso JA, Prince RA, Fox JL. Stability of ondansetron hydrochloride in injectable solutions at -20, 5, and 25°C. Am J Hosp Pharm 1992 ; 49: 2223-2225.
184	Žurnāls	Stewart JT, Warren FW, King DT, Fox JL. Stability of ondansetron hydrochloride and five antineoplasic medications. Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244	Žurnāls	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Žurnāls	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Žurnāls	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Žurnāls	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
266	Žurnāls	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
299	Žurnāls	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
301	Žurnāls	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Žurnāls	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
332	Žurnāls	Xu QA, Trissel LA, Fox JL. Compatibility of ondansetron hydrochloride with meperidine hydrochloride for combined administration. Ann Pharmacotherapy 1995 ; 29: 1106-1109.
333	Žurnāls	Graham CL, Dukes GE, Kao CF, Bertch JM, Hak LJ. Stability of ondansetron in large-volume parenteral solutions. Ann Pharmacotherapy 1992 ; 26: 768-771.
334	Žurnāls	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Žurnāls	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
492	Žurnāls	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
815	Žurnāls	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
905	Žurnāls	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
915	Žurnāls	Casto DT. Stability of ondansetron stored in polypropylene syringes. Ann Pharmacotherapy 1994 ; 28: 712-714.
917	Žurnāls	Blaise N, Vigneron J, Perrin A, Noirez V, Hoffman MA, Hoffman M. Stability of refrigerated and frozen solutions of ondansetron hydrochloride. EJHP 1994 ; 4: 12-13.
921	Žurnāls	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
969	Žurnāls	Jarosinski PF, Hirschfeld S. Precipitation of ondansetron in alkaline solutions. N Engl J Med 1991 ; 325: 1315-1316.
979	Žurnāls	D'Arcy PF. In vitro compatibility of granisetron with selected alkaline drugs. Int Pharm J 1995 ; 9: 57.
992	Žurnāls	Beijnen JH, Koks CHW. Visual compatibility of ondansetron and dexamethasone. Ann Pharmacotherapy 1991 ; 25: 869.
1026	Žurnāls	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1396	Žurnāls	Hauser AR, Trissel LA, Martinez JF. Ondansetron compatible with sodium acetate. J Clin Oncol 1993 ; 11: 197.
1410	Žurnāls	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Žurnāls	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Žurnāls	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Žurnāls	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Žurnāls	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Žurnāls	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1699	Žurnāls	Plaas S, Heck C, Kubrich M. Mischbarkeit von serotonin-antagonisten mit dexamethason und heparin. Krankenhauspharmazie 2000 ; 21: 107-109.
1712	Žurnāls	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1721	Žurnāls	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Žurnāls	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1800	Žurnāls	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Žurnāls	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1868	Žurnāls	Husson E, Crauste-Manciet S, Hadj-Salah E, ,Segier JC, Broissard D. Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange. Nutr Clin Metab 2003 ; 17: 8-14.
1925	Žurnāls	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Žurnāls	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2002	Žurnāls	Abanmy NO, Zaghloul IY, Radwan MA. Compatibility of tramadol hydrochloride injection with selected drugs and solutions. Am J Health-Syst Pharm 2005 ; 62: 1299-1302.
2012	Žurnāls	Bougouin C, Thelcide C, Crespin-Maillard F, Maillard C, Kinowski JM, Favier M. Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers. Am J Health-Syst Pharm 2005 ; 62: 2001-2005.
2108	Žurnāls	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2202	Žurnāls	Acin Lazaro MP, bono Arino C, martinez Bazan R, manzanares Marin I, Faci Bouthelier A, Velamazan Blocona MJ, Facorro Gaspar E, Estabilidad de parecoxib en dilucion con ostros farmacos y administrado en perfusion continua IV para el control del dolor postoperatorio. Investig Clin Farm 2005 ; 2, 4: 195-203.
2233	Žurnāls	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2261	Žurnāls	Fernandez C, Pelloquin A, Berthoume M, Bellanger A, Farinotti R. Stabilité et compatibilité de l'association ondansétron-méthylprednisolone en solution. Can J Hosp Pharm 2008 ; 61, 3: 191-195.
2262	Žurnāls	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Žurnāls	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2328	Laboratorija	Sugammadex (Bridion®) – Résumé des caractéristiques du produits Organon 2009
2841	Žurnāls	Gonzalves Navaro M, Carril Aviles M, Borras Almenar C, Romero Crespo I, Jimenez Torres NV. Estudio de estabilidad de la mezcla ondansetron-dexametasona en cloruro sodico 0,9%. Atencion Pharmaceutica 2009 ; 11, 3: 161-166.
3012	Žurnāls	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3174	Žurnāls	Rolin C, Hecq JD, Vanbeckbergen DF, Jamart J, Galanti LM. Stability of Ondansetron and Dexamethasone Infusion upon Refrigeration. Ann Pharmacotherapy 2011 ; 45: 130-131.
3249	Žurnāls	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Žurnāls	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3408	Žurnāls	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3459	Žurnāls	Sun S, Schaller J, Placek J, Duersch B. Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids. Cancer Chemother Pharmacol 2013 ; 72: 509-513.
3474	Laboratorija	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3571	Žurnāls	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3574	Laboratorija	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
3595	Laboratorija	Aciclovir - Summary of Product Characteristics Hospira 2009
3728	Žurnāls	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3791	Plakāts	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3824	Žurnāls	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Plakāts	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Plakāts	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Plakāts	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3925	Žurnāls	Simar J, Godet M, Hecq J.-D, Closset M, Gillet P, Langhendries C, Bihin B, Jamart J, Galanti L. Long-term stability of dexamethasone and alizapride or ondansetron in sodium chloride 0.9% polyolefin bag at 5±3 C. Ann Pharm Fr 2016 ; 75, 1 : 30-39.
3948	Žurnāls	Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416?424.
3964	Žurnāls	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3967	Žurnāls	Staven V, Herra I, Wang S, Grönlie I,Tho I. Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents. J Pharm Pharmacol 2017 ;69,7:448-462
3976	Žurnāls	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
3981	Žurnāls	He G, Zeng F, Lei K, Xia S, Deng L, Zhang C, Liu D. Compatibility of dexamethasone sodium phosphate with 5-HT3 receptor antagonists in infusion solutions: a comprehensive study EJHP 2017 ;24:162?166
4036	Žurnāls	Estan-Cerezo G, Matoses-Chirivella C, Soriano-Iriga L, Murcia-Lopez A.C, Rodrguez-Lucena F.J, Navarro-Ruiz A. Stability and compatibility of ondansetron with haloperidol in parenteral admixtures. EJHP 2017 ;25,4: 200-203.
4055	Žurnāls	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4082	Žurnāls	Espinosa-Bosch M, Sanchez-Rojas F, Bosche-Ojeda C. Stability of mixtures of ondansetron and haloperidol stored in infusors at different temperatures. EJHP 2018 ; 25, e2
4116	Žurnāls	Chen F, Zhu J, Li B, Yuan F, Wang K. Stability of tramadol with three 5-HT3 receptor antagonists in polyolefin bags for patient-controlled delivery systems. Drug Design Dev Ther 2016 ;10:1869-1875
4145	Žurnāls	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Žurnāls	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Žurnāls	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4429	Žurnāls	Fang B-X, Li P, Shi X-Y, Chen F.C, Wang L.H. Incompatibilities of lornoxicam with 4 antiemetic medications in polyolefin bags during simulated intravenous administration. Medicine 2016 ; 95:25(e3824)
4433	Žurnāls	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4479	Žurnāls	Closset M, Goderniaux N, Colsoul M-L, Soumoy L, Bihin B, Jamart J, Odou P, Hecq J-D, galanti L. Long term stability of an admixture of alizapride and ondansetron in 0.9% sodium chloride solution polyolefin bags stored at 5 +/- 3°C. J Oncol Pharm Practice 2020 ;27,6:1328-1332
4507	Žurnāls	Ross E, Salinas A, Petty K, Her C, Carpenter J. Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing. Am J Health-Syst Pharm 2020 ;77,23:1980-1985
4521	Žurnāls	Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020
4528	Žurnāls	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4579	Žurnāls	Tomczak S, Radwan V, Jelinska A, Stawny M. Application of the HPLC Method in Parenteral Nutrition Assessment: Stability Studies of Ondansetron Processes 2021 , 9, 453.
4650	Laboratorija	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4666	Žurnāls	Lee C.H, Kim A.R, Lee M.K, Oh J.S, Lee D.K, Choi S.S. Intravenous patient-controlled analgesia: in vitro stability profiles of mixtures containing fentanyl, hydromorphone, oxycodone, nefopam, ondansetron, and ramosetron. J Anal Sci Tech 2020 ; 11: 32.
4742	Žurnāls	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4776	Žurnāls	Tomczak S, Chmielewski, M, Szkudlarek J, Jeliinska A. Antiemetic Drugs Compatibility Evaluation with Paediatric Parenteral Nutrition Admixtures. Pharmaceutics 2023 ; 15: 2143.

Mentions Légales